Lakefront Biotherapeutics (LKFT) Retained Earnings (2013 - 2025)

Lakefront Biotherapeutics (LKFT) has reported Retained Earnings for 13 consecutive years, with -$10.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 86.0% year-over-year to -$10.1 million; the TTM figure through Mar 2026 stood at -$10.1 million (down 86.0% YoY), while the FY2025 annual figure was -$10.1 million, up 92.99% from the prior year.
• Retained Earnings was little changed at -$10.1 million in Q1 2026 per LKFT's latest filing, from -$10.1 million in the prior quarter.
• Across five years, Retained Earnings topped out at -$5.2 million in Q1 2023 and bottomed at -$506.7 million in Q4 2022.
• Historically, Retained Earnings has averaged -$56.9 million across 5 years, with a median of -$10.1 million in 2025.
• Annual changes were most pronounced in 2023 — Retained Earnings jumped 98.75% — and 2024, when it slumped 2164.67%.
• Lakefront Biotherapeutics' Retained Earnings stood at -$506.7 million in 2022, then surged by 98.75% to -$6.3 million in 2023, then sank by 2164.67% to -$143.5 million in 2024, then soared by 92.99% to -$10.1 million in 2025, then fell by 0.47% to -$10.1 million in 2026.
• Business Quant data shows LKFT's Retained Earnings at -$10.1 million in Q1 2026, -$10.1 million in Q4 2025, and -$10.9 million in Q3 2025.